Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,731.07
(
0.47%
)
US TECH 100
24,161.99
(
0.61%
)
Dow Jones
47,101.02
(
0.33%
)
Brent Oil
100.48
(
2.21%
)
Bitcoin
74,660.15
(
-0.25%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 67383

Tuesday, 10/14/2008 1:22:53 AM

Tuesday, October 14, 2008 1:22:53 AM

Post# of 257251
Today was a busy news day for ABT. In addition to announcing a $5B share buyback, ABT released data at the TCT conference on Xience and the bioabsorbable stent in development.

In head-to-head studies, Xience bested BSX’s Taxus on both MACE and TLR at two years:
http://biz.yahoo.com/prnews/081013/aqm519.html

ABT’s bioabsorbable stent demonstrated decent results and confirmed bioabsorption in a pilot single-arm study with 30 patients:
http://biz.yahoo.com/prnews/081013/aqm521.html

I think it’s fair to say that ABT is now generally perceived to be the technology leader in the field of drug-eluting stents.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now